期刊文献+

美国应用核酸检测筛查血液的历程和现状 被引量:4

The course and actualities of nucleic acid testing for blood screening in the United States
原文传递
导出
摘要 输血相关传染病的预防和控制已经成为全社会关注的焦点问题,而新的检测技术(如核酸检测)的引入是进一步提高血液安全的重要措施之一。此文综述了美国应用核酸检测筛查血液的历程和现状,以期对我国血液筛查策略的改进提供参考. it has been increasingly focused on the prevention and control of the transfusion-transmitted infectious diseases. The introduction of the new technology, such as nucleic acid testing (NAT) , is one of the important measures to improve the blood safety. This article will review the course and actualities of NAT for blood screening in the United States, and provide experience to ameliorate the blood screening strategy in China.
出处 《国际生物制品学杂志》 CAS 2009年第2期101-105,共5页 International Journal of Biologicals
关键词 血液筛查 核酸检测 病毒 美围 Blood screening Nucleic acid testing Virus The United States
  • 相关文献

参考文献8

  • 1Stramer SL. Viral diagnostics in the arena of blood donor screening [J]. Vox Sang, 2004, 87Suppl2:S180-183.
  • 2Strainer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing [J]. N Engl J Med, 2004, 351 C 8 ) : 760-768.
  • 3Orfinger B. Red Cross studies new blood safety measures [ EB/OL]. [ 2008-11-19]. http://www. redcross. org/news/bm/meeting/010322bpac. html.
  • 4Busch MP. Evolving approaches to estimate risks of transfusiontransmitted viral infections: incidence-window period model after ten years [ J]. Dev Biol ( Basel). 2007, 127:87-112.
  • 5Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk [ J ]. J Clin Virol, 2006, 36 Suppl 1 : S23-29.
  • 6Strainer SL. US NAT yield: where are we after 2 years? [J]. Transfus Med, 2002, 12(4) :243-253.
  • 7Marshall DA, Kleinman SH, Wong JB, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States [J]. Vox Sang, 2004, 86(1) :28-40.
  • 8Jackson BR, Busch MP, Stramer SL, et al. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion, 2003, 43(6) :721-729.

同被引文献73

引证文献4

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部